The Complexes of Mammalian Target of Rapamycin [PDF]
Current Protein & Peptide Science, 2010 The mammalian target of rapamycin (mTOR) has attracted substantial attention because of its involvement in a variety of diseases, such as cancer, cardiac hypertrophy, diabetes and obesity. Current knowledge indicates that mTOR functions as two distinct multiprotein complexes, mTORC1 and mTORC2.
Hongyu, Zhou, Shile, Huang
openaire +2 more sources
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source
Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2 [PDF]
Molecular Cell, 2015 Target of Rapamycin (TOR) plays central roles in the regulation of eukaryote growth as the hub of two essential multiprotein complexes: TORC1, which is rapamycin-sensitive, and the lesser characterized TORC2, which is not. TORC2 is a key regulator of lipid biosynthesis and Akt-mediated survival signaling.
Gaubitz, Christl +12 more
openaire +4 more sources
Investigating the effect of target of rapamycin kinase inhibition on the Chlamydomonas reinhardtii phosphoproteome: from known homologs to new targets [PDF]
, 2019 Recuperado de: https://www.biorxiv.org/content/10.1101/310102v1Target of rapamycin (TOR) kinase is a conserved regulator of cell growth whose activity is modulated in response to nutrients, energy and stress.
Couso Liáñez, Inmaculada Concepción +6 more
core +1 more source
Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade. [PDF]
PLoS ONE, 2013 While neurohumoral antagonists improve outcomes in heart failure (HF), cardiac remodeling and dysfunction progress and outcomes remain poor. Therapies superior or additive to standard HF therapy are needed.
Kalkidan Bishu +7 more
doaj +1 more source
PRAS40 suppresses atherogenesis through inhibition of mTORC1-dependent pro-inflammatory signaling in endothelial cells [PDF]
, 2019 Endothelial pro-inflammatory activation plays a pivotal role in atherosclerosis, and many pro-inflammatory and atherogenic signals converge upon mechanistic target of rapamycin (mTOR).
Althoff, Till F. +14 more
core +1 more source
Targeting the mTOR pathway in breast cancer
Tumor Biology, 2017 Mechanistic target of rapamycin controls cell growth, metabolism, and aging in response to nutrients, cellular energy stage, and growth factors. In cancers including breast cancer, mechanistic target of rapamycin is frequently upregulated.
Jia Liu +5 more
doaj +1 more source
Frontiers in Plant Science, 2016 Target of Rapamycin (TOR) signaling is an important regulator in multiple organisms including yeast, plants and animals. However, the TOR signaling in plants is much less understood as compared to that in yeast and animals.
Fangjie Xiong +9 more
doaj +1 more source
Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition
FEBS Open Bio, 2020 Lung cancer is the leading cause of cancer‐related death, and there remains a need for novel therapies for this malignancy. Here, we examined the effects of alpha‐lipoic acid (LA), a drug used for treating human diabetic complications, on lung cancer ...
Peipei Peng +7 more
doaj +1 more source
Dengue activates mTORC2 signaling to counteract apoptosis and maximize viral replication
Frontiers in Cellular and Infection Microbiology, 2022 The mechanistic target of rapamycin (mTOR) functions in two distinct complexes: mTORC1, and mTORC2. mTORC1 has been implicated in the pathogenesis of flaviviruses including dengue, where it contributes to the establishment of a pro-viral autophagic state.
Christoph C. Carter +15 more
doaj +1 more source